June 28, 2018 09:17 AM EDT
R&D

Tout­ing PhI­II suc­cess for arthri­tis drug Taltz, Eli Lil­ly chas­es ri­val No­var­tis in heat­ed im­munol­o­gy race

Brittany Meiling

Aim­ing for a new in­di­ca­tion to ex­pand the use — and sales — of its pso­ri­at­ic arthri­tis drug Taltz, Eli Lil­ly is spot­light­ing pos­i­tive Phase III re­sults …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times